CN: 32-1845/R
ISSN: 2095-6975
YAN Lin, DAI Yu-Xuan, GU Guo-Long, PAN Miao-Bo, WU Shuai-Cong, CAO Yu, HUANG Wen-Long. Design, synthesis, and biological evaluation of novel nitric oxide releasing dehydroandrographolide derivatives[J]. 中国天然药物英文, 2018, 16(10): 782-790

Design, synthesis, and biological evaluation of novel nitric oxide releasing dehydroandrographolide derivatives

YAN Lin1, DAI Yu-Xuan2, GU Guo-Long3, PAN Miao-Bo2, WU Shuai-Cong2, CAO Yu4, HUANG Wen-Long2,5
1 Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng 475004, China;
2 State Key Laboratory of Natural Medicines, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, China;
3 School of Pharmacy, Yancheng Teachers University, Yancheng 224007, China;
4 Department of Dermatology, First Affiliated Hospital of Guizhou Medical University, Guiyang 550025, China;
5 Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, China
A series of new hybrids of dehydroandrographolide (TAD), a biologically active natural product, bearing nitric oxide (NO)-releasing moieties were synthesized and designated as NO-donor dehydroandrographolide. The biological activities of target compounds were studied in human erythroleukemia K562 cells and breast cancer MCF-7 cells. Biological evaluation indicated that the most active compound I-5 produced high levels of NO and inhibited the proliferation of K562 (IC50 1.55 μmol·L-1) and MCF-7 (IC50 2.91 μmol·L-1) cells, which were more potent than the lead compound TAD and attenuated by an NO scavenger. In conclusion, I-5 is a novel hybrid with potent antitumor activity and may become a promising candidate for future intensive study.
关键词:    Tehydroandrographolide    Nitric oxide    Anticancer   
收稿日期: 2018-05-21
CAO Yu,;HUANG Wen-Long,
PDF(524 KB) Free
YAN Lin 在本刊中的所有文章
DAI Yu-Xuan 在本刊中的所有文章
GU Guo-Long 在本刊中的所有文章
PAN Miao-Bo 在本刊中的所有文章
WU Shuai-Cong 在本刊中的所有文章
CAO Yu 在本刊中的所有文章
HUANG Wen-Long 在本刊中的所有文章
[1] Abu-Ghefreh AA, Canatan H, Ezeamuzie CI. In vitro and in vivo anti-inflammatory effects of andrographolide[J]. Int Immunopharmacol, 2009, 9(3):313-318.
[2] Bao Z, Guan SP, Cheng C, et al. A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-kappa B pathway[J]. Am J Respir Crit Care Med, 2013, 179(8):657-665.
[3] Jiang CG, Li JB, Liu FR, et al. Andrographolide inhibits the adhesion of gastric cancer cells to endothelial cells by blocking E-selectin expression[J]. Anticancer Res, 2007, 27(4B):2439-2447.
[4] Mishra SK, Tripathi S, Shukla A, et al. Andrographolide and analogues in cancer prevention[J]. Front Biosci, 2015, 7(2):292-304.
[5] Banerjee A, Ahmed H, Yang P, et al. Endoplasmic reticu-lum stress and IRE-1 signaling cause apoptosis in colon cancer cells in response to andrographolide treatment[J]. Oncotarget, 2016, 7(27):41432-41444.
[6] Banerjee A, Banerjee V, Czinn S, et al. Increased reactive oxygen species levels cause ER stress and cytotoxicity in andrographolide treated colon cancer cells[J]. Oncotarget, 2017, 8(16):26142-26153.
[7] Lougiakis N, Papapetropoulos A, Gikas E, et al. Synthesis and pharmacological evaluation of novel adenine-hydrogen sulfide slow release hybrids designed as multitarget cardioprotective agents[J]. J Med Chem, 2016, 59(5):1776-1790.
[8] Coletta C, Papapetropoulos A, Erdelyi K, et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation[J]. Proc Natl Acad Sci USA, 2012, 109(23):9161-9166.
[9] Ai Y, Kang F, Huang Z, et al. Synthesis of CDDO-Amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer[J]. J Med Chem, 2015, 58(5):2452-2464.
[10] Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression[J]. Nat Rev Cancer, 2006, 6(7):521-534.
[11] Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system:A historical overview[J]. J Physiol Pharmacol, 2002, 53(4):503-514.
[12] Radomski MW, Palmer RMJ. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium[J]. Biochem Bioph Res Co, 1987, 148(3):1482-1489.
[13] Lanas A. Role of nitric oxide in the gastrointestinal tract[J]. Arthritis Res Ther, 2008, 10(Suppl 2):S4-S4.
[14] Schwentker A, Vodovotz Y, Weller R, et al. Nitric oxide and wound repair:role of cytokines?[J]. Nitric Oxide, 2002, 7(1):1-10.
[15] Bonavida B, Baritaki S, Huertayepez S, et al. Novel therapeutic applications of nitric oxide donors in cancer:Roles in chemo-and immunosensitization to apoptosis and inhibition of metastases[J]. Nitric Oxide, 2008, 19(2):152-157.
[16] Riganti C, Miraglia E, Viarisio D, et al. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux[J]. Cancer Res, 2005, 65(2):516-525.
[17] Sullivan R, Graham CH. Chemosensitization of cancer by nitric oxide[J]. Curr Pharm Des, 2008, 14(11):1113-1123.
[18] Chen L, Zhang YH, Kong XW, et al. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid[J]. J Med Chem, 2008, 51(15):4834-4838.
[19] Han C, Zheng C, Wan L, et al. Novel hybrids of (phenylsulfonyl) furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer[J]. J Med Chem, 2013, 56(11):4738-4748.
[20] Tang X, Gu X, Ai H, et al. Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells[J]. Bioorg Med Chem Lett, 2012, 22(2):801-805.
[21] Turnbull CM, Cena C, Fruttero R, et al. Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets[J]. Brit J Pharmacol, 2006, 148(4):517-526.
[22] Turnbull CM, Marcarino P, Sheldrake TA, et al. A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages[J]. J Inflamm-Lond, 2008, 5(1):12.
[23] Xu H, Zhang J, Liu H, et al. Synthesis of andrographolide cyclophosphate derivatives and their antitumor activities[J]. Cheminform, 2006, 36(4):407-414.
[24] Tang C, Liu Y, Wang B, et al. Synthesis and biological evaluation of andrographolide derivatives as potent anti-HIV agents[J]. Archiv Der Pharmazie, 2012, 345(8):647-656.
[25] Gu G, Lin HY, Liu Y, et al. Synthesis and anti-HIV-evaluation of novel andrographolide derivatives[J]. Lett Drug Des Discov, 2013, 10(2):155-163.
[26] Chen L, Zhang Y, Kong X, et al. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid[J]. J Med Chem, 2008, 51(15):4834-4838.
[27] Visentin S, Rolando B, Di Stilo A, et al. New 1, 4-dihydro-pyridines endowed with NO-donor and calcium channel agonist properties[J]. J Med Chem, 2004, 47(10):2688-2693.
[28] Ling Y, Ye X, Zhang Z, et al. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid:synthesis and evaluation of antihepatocellular carcinoma activity[J]. J Med Chem, 2011, 54(9):3251-3259.
[29] Li D, Wang L, Cai H, et al. Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents[J]. Molecules, 2012, 17(6):7556-7568.
[30] Wang PG, Xian M, Tang XP, et al. Nitric oxide donors:Chemical activities and biological applications[J]. Chem Rev, 2002, 102(4):1091-1134.
[31] Miller MR, Megson IL. Recent developments in nitric oxide donor drugs[J]. Br J Pharmacol, 2007, 151(3):305-321.
[32] Huang Z, Fu J, Zhang Y. Nitric oxide donor-based cancer therapy:advances and prospects[J]. J Med Chem, 2017, 60(18):7617-7635.
[33] Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines:molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity[J]. Pharmacol Rev, 2004, 56(2):185-229.